Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas
This article was originally published in PharmAsia News
Executive Summary
Merck & Co. is acquiring North American rights to intravenous vernakalant from Astellas Pharma's U.S. subsidiary, Merck announced on July 26. The agreement will consolidate its interest in the cardiovascular drug to include worldwide rights to both the IV and oral formulations